Sadaaki Miyakawa

N1-(2 tetrahydrofuryl)-5-fluorouracil (ft-207) in the postoperative adjuvant chemotherapy of gastric cancer. Delivery of a fat-emulsified agent to the lymph

The influence of fat emulsification of N1‐(2‐tetrahydrofuryl)‐5‐fluorouracil (FT‐207) on lymphatic transport was studied in seven postoperative gastric cancer patients. The water‐in‐oil‐type of emulsion of FT‐207 (FT‐w/o), the oil‐in‐water‐type emulsion of FT‐207 (FT‐o/w) and an enteric‐coated granule of FT‐207 (FT‐G) each in 1‐g doses, calculated in terms of FT‐207, were administered orally. Lymph from a thoracic duct fistula, prepared in advance, and from the blood of a peripheral vein was collected simultaneously along a time course after administration to measure the concentrations of FT‐207 and 5‐fluorouracil (5‐FU). For FT‐w/o, FT‐207, and 5‐FU, concentrations were significantly higher, both in the lymph and in the blood, than those for FT‐G and FT‐o/w. However, no significant differences in FT‐207 and 5‐FU concentrations were observed between FT‐o/w and FT‐G. It was concluded that FT‐w/o can be useful as an adjuvant chemotherapeutic drug in the postoperative treatment of gastric cancer.